{"id":181359,"date":"2023-04-05T00:00:00","date_gmt":"2023-04-04T22:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/le-rimegepant-une-nouvelle-option-therapeutique-pour-la-migraine-2\/"},"modified":"2023-04-05T00:00:00","modified_gmt":"2023-04-04T22:00:00","slug":"le-rimegepant-une-nouvelle-option-therapeutique-pour-la-migraine-2","status":"publish","type":"post","link":"https:\/\/cbip.be\/fr\/le-rimegepant-une-nouvelle-option-therapeutique-pour-la-migraine-2\/","title":{"rendered":"Le rim\u00e9g\u00e9pant : une nouvelle option th\u00e9rapeutique pour la migraine"},"content":{"rendered":"<div class=&quot;summary&quot;>Le rim\u00e9g\u00e9pant appartient \u00e0 la classe des antagonistes des r\u00e9cepteurs du peptide li\u00e9 au g\u00e8ne de la calcitonine<i> <\/i>(CGRP)&#x002C; une nouvelle classe de m\u00e9dicaments pour la migraine appel\u00e9s \u00ab\u00a0g\u00e9pants\u00a0\u00bb.<br \/> \u00a0<br \/> Que ce soit en aigu ou en prophylaxie&#x002C; l\u2019effet du rim\u00e9g\u00e9pant est plut\u00f4t modeste. Avec le rim\u00e9g\u00e9pant&#x002C; la douleur avait disparu 2 heures apr\u00e8s la prise chez 5 \u00e0 16% de patients suppl\u00e9mentaires&#x002C; par rapport au placebo. L&#39;administration prophylactique de rim\u00e9g\u00e9pant (tous les deux jours) permet d\u2019\u00e9viter moins d&#39;un jour de migraine dans le troisi\u00e8me mois suivant le d\u00e9but du traitement&#x002C; par rapport au placebo.<br \/> \u00a0<br \/> Des \u00e9tudes comparatives directes sont n\u00e9cessaires entre le rim\u00e9g\u00e9pant et les autres traitements m\u00e9dicamenteux utilis\u00e9s dans la migraine aigu\u00eb ou en prophylaxie.<br \/> \u00a0<br \/> Le rim\u00e9g\u00e9pant pourrait \u00eatre une alternative int\u00e9ressante pour les patients qui ne r\u00e9pondent pas suffisamment aux triptans ou qui pr\u00e9sentent des contre-indications aux triptans&#x002C; mais ce groupe n\u2019a pas encore \u00e9t\u00e9 \u00e9tudi\u00e9.<br \/> \u00a0<br \/> Il n&#39;existe pas non plus d&#39;\u00e9tudes randomis\u00e9es sur l&#39;utilit\u00e9 du rim\u00e9g\u00e9pant en traitement de crise chez les patients prenant d\u00e9j\u00e0 du rim\u00e9g\u00e9pant \u00e0 titre prophylactique ou recevant un autre traitement prophylactique.<\/p>\n<p> Des recherches suppl\u00e9mentaires sont n\u00e9cessaires pour \u00e9valuer l\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 \u00e0 long terme du rim\u00e9g\u00e9pant.<\/p><\/div>\n<h2>Les antagonistes du r\u00e9cepteur du CGRP : une nouvelle classe d\u2019antimigraineux<\/h2>\n<ul>\n<li>\n<p>Le rim\u00e9g\u00e9pant est le premier antimigraineux autoris\u00e9 en Europe d\u2019une nouvelle classe de m\u00e9dicaments antimigraineux : les petites mol\u00e9cules antagonistes (<a>non-peptidiques<\/a>) des r\u00e9cepteurs du peptide reli\u00e9 au g\u00e8ne de la calcitonine (CGRP)&#x002C; aussi appel\u00e9es les \u00ab\u00a0<strong>g\u00e9pants\u00a0\u00bb<\/strong>. Le CGRP est un neuropeptide impliqu\u00e9 dans la physiopathologie de la migraine<span class=&quot;folia-referentie-nummer&quot;><sup>1<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282200\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Heersche<\/Author><Year>2018<\/Year><RecNum>17410<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>1<\/style>\n\n<\/DisplayText><record><rec-number>17410<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>17410<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Heersche&#x002C;A. <\/author><author>Bijlstra-Cramer&#x002C;M. A. <\/author><\/authors><\/contributors><titles><title>Erenumab; de eerste CGRP-antagonist bij migraine<\/title><secondary-title>Pharma Selecta<\/secondary-title><\/titles><pages>65-68<\/pages><volume>34<\/volume><dates><year>2018<\/year><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=17410.pdf<\/url><\/pdf-urls><\/urls><access-date>2018-10-01<\/access-date><modified-date>H\u00b0 Zen; TF Mig<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><\/p>\n<\/li>\n<li>\n<p>Le rim\u00e9g\u00e9pant est administr\u00e9 sous forme de lyophilisat oral (\u00e0 placer sur ou sous la langue) \u00e0 raison de 75 mg par lyophilisat. La posologie est de 75 mg en cas de crise aigu\u00eb (maximum 1x par jour) et de 75 mg tous les deux jours en prophylaxie (maximum 75 mg par jour). Selon le RCP&#x002C; le rim\u00e9g\u00e9pant est indiqu\u00e9 \u00e0 la fois pour le traitement des <strong>crises de migraine<\/strong> avec ou sans aura chez l\u2019adulte et pour la <strong>prophylaxie de la migraine<\/strong> <strong>\u00e9pisodique <\/strong>chez les adultes qui pr\u00e9sentent au moins 4 crises de migraine par mois. Le rim\u00e9g\u00e9pant n&#39;est pas rembours\u00e9 en Belgique (situation au 01\/02\/2023&#x002C; pour le prix actuel <a href=&quot;https:\/\/www.cbip.be\/fr\/chapters\/11?frag=8903122&quot;>voir le R\u00e9pertoire<\/a>).<\/p>\n<\/li>\n<li>\n<p>Une autre classe d&#39;antimigraineux qui agissent sur le CGRP ou son r\u00e9cepteur sont les anticorps monoclonaux anti-CGRP (uniquement en prophylaxie)&#x002C; dont trois sont actuellement commercialis\u00e9s en Belgique [voir <a href=&quot;https:\/\/www.cbip.be\/fr\/articles\/3662?folia=3658&quot;>Folia d\u2019ao\u00fbt 2021<\/a>]. Autre nouveaut\u00e9 qui ne devrait pas tarder \u00e0 appara\u00eetre dans le paysage th\u00e9rapeutique belge\u00a0: les agonistes des r\u00e9cepteurs 5HT<sub>1F<\/sub> pour le traitement de crise&#x002C; \u00e9galement appel\u00e9s les \u00ab\u00a0ditans\u00a0\u00bb <!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height: 150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:FR-BE;mso-fareast-language:EN-US; mso-bidi-language:AR-SA\u2019><span style=\u2019mso-spacerun:yes\u2019>\u00a0<\/span>ADDIN EN.CITE <EndNote><Cite><Author>Schwarz<\/Author><Year>2022<\/Year><RecNum>26417<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>2<\/style>\n\n<\/DisplayText><record><rec-number>26417<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>26417<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Schwarz&#x002C;E. P. <\/author><\/authors><\/contributors><titles><title>Nieuw geneesmiddel: rimegepant bij migraineaanvallen<\/title><secondary-title>Geneesmiddelenbulletin<\/secondary-title><\/titles><pages>65-8<\/pages><volume>8<\/volume><dates><year>2022<\/year><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26417.pdf<\/url><\/pdf-urls><\/urls><access-date>2022\/08\/02 tot 2022\/08\/15<\/access-date><modified-date>H\u00b0 Psy; ISDB<\/modified-date><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>2<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]--> (autoris\u00e9s en Europe mais pas encore commercialis\u00e9s en Belgique).<\/p>\n<\/li>\n<li>\n<p>Outre le rim\u00e9g\u00e9pant&#x002C; deux <b>autres<\/b> \u00ab\u00a0<b>g\u00e9pants\u00a0\u00bb <\/b>ont \u00e9t\u00e9 autoris\u00e9s<b> <\/b>aux Etats-Unis (situation au 01\/02\/2023) : l&#39;atog\u00e9pant pour la prophylaxie antimigraineuse et l&#39;ubrog\u00e9pant pour le traitement de la migraine aigu\u00eb.<br \/> \u00a0<\/p>\n<\/li>\n<\/ul>\n<h2>Efficacit\u00e9 du rim\u00e9g\u00e9pant dans la migraine aigu\u00eb<\/h2>\n<div class=&quot;summary&quot;>Selon des \u00e9tudes randomis\u00e9es&#x002C; entre 19\u00a0et\u00a031% des patients ne ressentent plus de douleur deux heures apr\u00e8s la prise de rim\u00e9g\u00e9pant&#x002C; soit 5 \u00e0 16 % de plus qu&#39;avec un placebo. Les \u00e9tudes incluaient principalement des femmes et l&#39;\u00e2ge moyen des participants \u00e9tait de 40 \u00e0 42 ans. Les patients avaient en moyenne 4 \u00e0 4&#x002C;6 crises de migraine par mois au d\u00e9but de l&#39;\u00e9tude. Les patients souffrant de maladies cardiovasculaires graves ou de troubles psychiatriques ont \u00e9t\u00e9 exclus.<br \/> Des \u00e9tudes compl\u00e9mentaires sont n\u00e9cessaires pour savoir si le rim\u00e9g\u00e9pant garde son effet lorsqu\u2019il est utilis\u00e9 de mani\u00e8re r\u00e9p\u00e9t\u00e9e pour des crises de migraine r\u00e9currentes.<br \/> La place du rim\u00e9g\u00e9pant dans l\u2019arsenal th\u00e9rapeutique de la crise de migraine reste incertaine pour l&#39;instant.<\/div>\n<h3>Le rim\u00e9g\u00e9pant en traitement de crise compar\u00e9 au placebo<\/h3>\n<ul>\n<li>\n<p>Selon des <b>\u00e9tudes randomis\u00e9es <\/b>men\u00e9es sur un total de 4 700 patients (entre 2 et 8 crises de migraine par mois&#x002C; maximum 15 jours de c\u00e9phal\u00e9es par mois)&#x002C; <b>5 \u00e0 16% de patients suppl\u00e9mentaires <\/b>\u00e9taient <b>sans douleur <\/b>deux heures apr\u00e8s la prise de rim\u00e9g\u00e9pant 75 mg (entre 19\u00a0et 31% sans douleur)&#x002C; par rapport au placebo. Le <b>sympt\u00f4me le plus invalidant <\/b>(photophobie&#x002C; phonophobie&#x002C; naus\u00e9es ou vomissements) avait disparu au bout de 2 heures chez environ 1 patient sur 3&#x002C; contre environ 1 patient sur 4 sous placebo. (voir + Plus d&#39;infos \u00ab Le rim\u00e9g\u00e9pant en traitement de crise compar\u00e9 \u00e0 d&#39;autres m\u00e9dicaments \u00bb)<\/p>\n<\/li>\n<li>\n<p><b>Les participants \u00e0 l&#39;\u00e9tude <\/b>\u00e9taient principalement des femmes (85 \u00e0 89%) et leur \u00e2ge moyen \u00e9tait de 40 \u00e0 42 ans. Les patients pouvaient \u00eatre sous prophylaxie antimigraineuse stable \u00e0 condition que la prophylaxie ait \u00e9t\u00e9 initi\u00e9e au moins 3 mois avant leur inclusion. Il n&#39;est pas pr\u00e9cis\u00e9 combien de patients \u00e9taient effectivement sous r\u00e9gime prophylactique\u00a0ni quel \u00e9tait le traitement m\u00e9dicamenteux utilis\u00e9 dans ce cas-l\u00e0.<\/p>\n<\/li>\n<li>\n<p>Les patients souffrant d\u2019une <b>maladie cardiovasculaire <\/b>non contr\u00f4l\u00e9e&#x002C; instable ou r\u00e9cemment diagnostiqu\u00e9e n&#39;ont pas \u00e9t\u00e9 inclus dans les \u00e9tudes en raison du risque th\u00e9orique d&#39;un effet vasoconstricteur avec les inhibiteurs du CGRP. Ce crit\u00e8re d&#39;exclusion co\u00efncide largement avec les contre-indications aux triptans&#x002C; ce qui explique la faible proportion de sujets pr\u00e9sentant des contre-indications aux triptans dans les \u00e9tudes sur le rim\u00e9g\u00e9pant (0&#x002C;4 \u00e0 1&#x002C;2 %)<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height: 150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:FR-BE;mso-fareast-language:EN-US; mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>EMA<\/Author><RecNum>26646<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>3<\/style>\n\n<\/DisplayText><record><rec-number>26646<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>26646<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>EMA&#x002C;<\/author><\/authors><\/contributors><titles><title>EPAR-Assessment Report Vydura\u00ae<\/title><\/titles><dates><\/dates><urls><related-urls><url>https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vydura<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26646.pdf<\/url><\/pdf-urls><\/urls><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>3<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->. Autre crit\u00e8re d\u2019exclusion\u00a0: les patients souffrant d&#39;une maladie h\u00e9patique existante et les patients ayant re\u00e7u un diagnostic de d\u00e9pression majeure ou ayant d&#39;autres <b>troubles psychiatriques<\/b>.<\/p>\n<\/li>\n<li>\n<p>Nous n&#39;avons trouv\u00e9 aucune \u00e9tude randomis\u00e9e ayant sp\u00e9cifiquement \u00e9valu\u00e9 l&#39;effet du rim\u00e9g\u00e9pant en traitement de crise chez les patients <b>prenant d\u00e9j\u00e0 du rim\u00e9g\u00e9pant \u00e0 titre prophylactique ou recevant un autre traitement prophylactique<\/b>. Des rapports de cas sugg\u00e8rent que le rim\u00e9g\u00e9pant permet d\u2019att\u00e9nuer les crises de migraine chez les patients prenant des <b>anticorps monoclonaux <\/b>en prophylaxie<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height: 150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:FR-BE;mso-fareast-language:EN-US; mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <\/span><span style=\u2019font-size:12.0pt; line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:NL-BE;mso-fareast-language:EN-US; mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:FR-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-spacerun:yes\u2019>\u00a0<\/span>ADDIN EN.CITE.DATA <\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><![if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]><span style=\u2019mso-element:field-end\u2019><\/span><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>4-6<\/sup><\/span><!--[if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]--><!--[if supportFields]><span style=\u2019font-size:12.0pt; line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:NL-BE;mso-fareast-language:EN-US; mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->&#x002C; mais des recherches suppl\u00e9mentaires sont n\u00e9cessaires.<\/p>\n<\/li>\n<\/ul>\n<h3>Le rim\u00e9g\u00e9pant en traitement de crise compar\u00e9 \u00e0 d&#39;autres m\u00e9dicaments<\/h3>\n<ul>\n<li>\n<p>Les \u00e9tudes ayant \u00e9valu\u00e9 l&#39;efficacit\u00e9 du rim\u00e9g\u00e9pant <b>par rapport aux autres traitements de crise des migraines <\/b>sont rares :<\/p>\n<ul>\n<li>\n<p>La seule \u00e9tude\u00a0<b>RCT comparative directe <\/b>\u00e9tait une \u00e9tude de \u00ab\u00a0recherche de dose<i>\u00a0\u00bb <\/i>ayant \u00e9valu\u00e9 une administration unique de rim\u00e9g\u00e9pant (\u00e0 diff\u00e9rentes doses)&#x002C; de <b>sumatriptan 100 mg <\/b>ou d\u2019un placebo<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282348\u2019> ADDIN EN.CITE <\/span><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282348\u2019><span style=\u2019mso-spacerun:yes\u2019>\u00a0<\/span>ADDIN EN.CITE.DATA <![if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]><\/span><span style=\u2019mso-element:field-end\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282348\u2019><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>4&#x002C; 6&#x002C; 7<\/sup><\/span><!--[if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]--><!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->. Par rapport au placebo&#x002C; le taux de r\u00e9ponse semblait l\u00e9g\u00e8rement meilleur avec le sumatriptan 100 mg (35% des patients sans douleur apr\u00e8s 2 heures) qu&#39;avec le rim\u00e9g\u00e9pant 75 mg (31&#x002C;4% sans douleur)&#x002C; mais il n&#39;y a pas eu de test statistique pour la comparaison rim\u00e9g\u00e9pant versus sumatriptan. Le rim\u00e9g\u00e9pant et le sumatriptan \u00e9taient tous deux plus efficaces que le placebo (15&#x002C;3 % de personnes sans douleur apr\u00e8s 2 heures) (voir + Plus d&#39;infos).<\/p>\n<\/li>\n<li>\n<p>Une <b>m\u00e9ta-analyse en r\u00e9seau<\/b> de plusieurs RCT en double aveugle concluait que le rim\u00e9g\u00e9pant \u00e9tait moins efficace que la plupart des triptans&#x002C; mais cette conclusion \u00e9tait seulement bas\u00e9e sur des comparaisons indirectes et&#x002C; selon les auteurs de la m\u00e9ta-analyse&#x002C; il y avait un biais de publication<!--[if supportFields]><sup><span lang=FR-BE style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:FR-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span> ADDIN EN.CITE <span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-spacerun:yes\u2019>\u00a0<\/span>ADDIN EN.CITE.DATA <![if gte mso 9]><xml> <\/xml><![endif]><span style=\u2019mso-element:field-end\u2019><\/span><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/sup><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>2&#x002C; 8<!--[if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]--><\/sup><\/span><!--[if supportFields]><sup><span lang=FR-BE style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:FR-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><\/sup><![endif]-->. En outre&#x002C; les populations ne sont pas tout \u00e0 fait comparables. (voir + Plus d&#39;infos)<\/p>\n<\/li>\n<li>\n<div class=&quot;detailed-content&quot;>\n<ul>\n<li>Via nos sources&#x002C; nous avons trouv\u00e9 les RCT suivantes sur le rim\u00e9g\u00e9pant en traitement de crise :<br \/> \u00a0 \u00a0 \u00a0&#8211;\u00a0Une \u00e9tude de &quot;recherche de dose&quot; de phase II ayant randomis\u00e9 les patients sur une<br \/> \u00a0 \u00a0 \u00a0 \u00a0administration unique de rim\u00e9g\u00e9pant (doses de 10 \u00e0 600 mg)&#x002C; de sumatriptan 100 mg et un<br \/> \u00a0 \u00a0 \u00a0 \u00a0placebo<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282415\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Marcus<\/Author><Year>2014<\/Year><RecNum>27254<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>7<\/style>\n\n<\/DisplayText><record><rec-number>27254<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>27254<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Marcus&#x002C;Ronald<\/author><author>Goadsby&#x002C;Peter J<\/author><author>Dodick&#x002C;David<\/author><author>Stock&#x002C;David<\/author><author>Manos&#x002C;George<\/author><author>Fischer&#x002C;Tanya Z<\/author><\/authors><\/contributors><auth-address>Bristol-Myers Squibb&#x002C; Wallingford&#x002C; CT&#x002C; USA.<\/auth-address><titles><title>BMS-927711 for the acute treatment of migraine: a double-blind&#x002C; randomized&#x002C; placebo controlled&#x002C; dose-ranging trial.<\/title><secondary-title>Cephalalgia<\/secondary-title><\/titles><pages>114-25<\/pages><volume>34<\/volume><number>2<\/number><dates><year>2014<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23965396<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27254.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1177\/0333102413500727<\/electronic-resource-num><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>7<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<br \/> \u00a0 \u00a0 \u00a0&#8211;\u00a0Trois \u00e9tudes de phase III ayant compar\u00e9 une administration unique de rim\u00e9g\u00e9pant 75 mg \u00e0<br \/> \u00a0 \u00a0 \u00a0 \u00a0un\u00a0placebo<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282441\u2019> ADDIN EN.CITE <\/span><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282441\u2019><span style=\u2019mso-spacerun:yes\u2019>\u00a0<\/span>ADDIN EN.CITE.DATA <![if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]><\/span><span style=\u2019mso-element:field-end\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282441\u2019><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>3&#x002C; 9&#x002C; 10<\/sup><\/span><!--[if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]--><!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE;mso-fareast-language: NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->.\n<p> \u00a0 \u00a0 \u00a0Toutes les \u00e9tudes incluaient des adultes souffrant de migraine avec ou sans aura&#x002C; ayant 2 \u00e0 8<br \/> \u00a0 \u00a0 \u00a0crises de migraine par mois (en moyenne 4 \u00e0 4&#x002C;6) et moins de 15 jours de c\u00e9phal\u00e9es par mois.<br \/> \u00a0<br \/> Crit\u00e8res d&#39;\u00e9valuation primaires :<br \/> \u00a0 \u00a0 \u00a0&#8211;\u00a0Pourcentage de patients sans douleur 2 heures apr\u00e8s la prise ;<br \/> \u00a0 \u00a0 \u00a0&#8211;\u00a0Pourcentage de patients dont le sympt\u00f4me migraineux le plus invalidant (naus\u00e9e&#x002C;<br \/> \u00a0 \u00a0 \u00a0 \u00a0vomissement&#x002C; photophobie ou phonophobie) avait disparu 2 heures apr\u00e8s la prise du<br \/> \u00a0 \u00a0 \u00a0 \u00a0m\u00e9dicament.<\/li>\n<\/ul>\n<p> Tableau : \u00e9tudes randomis\u00e9es contr\u00f4l\u00e9es par placebo avec le rim\u00e9g\u00e9pant en traitement de crise des migraines<br \/> \u00a0 <\/p>\n<table border=&quot;1&quot; cellpadding=&quot;1&quot; cellspacing=&quot;1&quot; style=&quot;width:600px;&quot;>\n<tbody>\n<tr>\n<td>\u00c9tude<\/td>\n<td>Intervention<\/td>\n<td>Crit\u00e8res d&#39;\u00e9valuation cliniques<\/td>\n<td>R\u00e9sultat<\/td>\n<\/tr>\n<tr>\n<td>RCT de &quot;recherche de dose&quot; aupr\u00e8s de 886 adultes pr\u00e9sentant 2 \u00e0 7 crises de migraine par mois<span class=&quot;folia-referentie-nummer&quot;><sup>7<\/sup><\/span><\/td>\n<td>Rim\u00e9g\u00e9pant 10-600\u00a0mg vs.<br \/> sumatriptan 100 mg vs. placebo<\/td>\n<td>Disparition de la douleur apr\u00e8s 2h<br \/> (92% ont termin\u00e9 l&#39;\u00e9tude)<\/td>\n<td>Rim\u00e9g\u00e9pant<br \/> 75 mg : 31&#x002C;4%<br \/> 150 mg : 32&#x002C;9%<br \/> 300 mg : 29&#x002C;7%<br \/> (p<0&#x002C;05 vs. placebo)<br \/> \u00a0<br \/> Sumatriptan 35%<br \/> (p<0&#x002C;05 vs. placebo)<br \/> \u00a0<br \/> Placebo 15&#x002C;3%<\/td>\n<\/tr>\n<tr>\n<td>RCT aupr\u00e8s de 1 186 adultes pr\u00e9sentant 2 \u00e0 8 crises de migraine par mois<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span> ADDIN EN.CITE <EndNote><Cite><Author>Lipton<\/Author><Year>2019<\/Year><RecNum>19361<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>9<\/style>\n\n<\/DisplayText><record><rec-number>19361<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>19361<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Lipton&#x002C;R. B. <\/author><author>Croop&#x002C;R. <\/author><author>Stock&#x002C;E. G. <\/author><author>Stock&#x002C;D. A. <\/author><author>Morris&#x002C;B. A. <\/author><author>Frost&#x002C;M. <\/author><author>Dubowchik&#x002C;G. M. <\/author><author>Conway&#x002C;C. M. <\/author><author>Coric&#x002C;V. <\/author><author>Goadsby&#x002C;P. J. <\/author><\/authors><\/contributors><auth-address>From the Departments of Neurology and Epidemiology and Population Health&#x002C; Albert Einstein College of Medicine&#x002C; and Montefiore Medical Center - both in Bronx&#x002C; NY (R.B.L.); Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT (R.C.&#x002C; E.G.S.&#x002C; D.A.S.&#x002C; B.A.M.&#x002C; M.F.&#x002C; G.M.D.&#x002C; C.M.C.&#x002C; V.C.); NIHR-Wellcome Trust King&apos;s Clinical Research Facility&#x002C; King&apos;s College Hospital-South London and Maudsley Biomedical Research Centre&#x002C; King&apos;s College London&#x002C; London (P.J.G.); and the University of California&#x002C; San Francisco&#x002C; San Francisco (P.J.G.).<\/auth-address><titles><title>Rimegepant&#x002C; an oral calcitonin gene-related peptide receptor antagonist&#x002C; for migraine<\/title><secondary-title>N Engl J Med<\/secondary-title><\/titles><pages>142-149<\/pages><volume>381<\/volume><number>2<\/number><dates><year>2019<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31291516<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=19361.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1056\/NEJMoa1811090<\/electronic-resource-num><access-date>2019-08-15<\/access-date><modified-date>H\u00b0 Zen; H\u00b0 Pijn; TF Mig<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>9<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]--><\/td>\n<td>Rim\u00e9g\u00e9pant<br \/> 75 mg vs. placebo<br \/> (administration unique)<\/td>\n<td>Disparition de la douleur apr\u00e8s 2h<br \/> (90% ont termin\u00e9 l&#39;\u00e9tude)<\/p>\n<p> Disparition du sympt\u00f4me le plus invalidant apr\u00e8s 2\u00a0h<\/td>\n<td>19&#x002C;6% contre 12%<br \/> Diff\u00e9rence de 7&#x002C;6% (IC \u00e0 95% de 3&#x002C;3 \u00e0 11&#x002C;9)<\/p>\n<p> 37&#x002C;6% contre 25&#x002C;2%<br \/> Diff\u00e9rence de 12&#x002C;4% (IC \u00e0 95% de 6&#x002C;9 \u00e0 17&#x002C;9)<\/p>\n<p> \u00a0<\/td>\n<\/tr>\n<tr>\n<td>RCT aupr\u00e8s de 1 466 adultes pr\u00e9sentant 2 \u00e0 8 crises de migraine par mois<!--[if supportFields]><span style=\u2019font-size:12.0pt; line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:NL-BE;mso-fareast-language:NL-BE; mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:FR-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Lipton<\/Author><Year>2019<\/Year><RecNum>19361<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>9<\/style>\n\n<\/DisplayText><record><rec-number>19361<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>19361<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Lipton&#x002C;R. B. <\/author><author>Croop&#x002C;R. <\/author><author>Stock&#x002C;E. G. <\/author><author>Stock&#x002C;D. A. <\/author><author>Morris&#x002C;B. A. <\/author><author>Frost&#x002C;M. <\/author><author>Dubowchik&#x002C;G. M. <\/author><author>Conway&#x002C;C. M. <\/author><author>Coric&#x002C;V. <\/author><author>Goadsby&#x002C;P. J. <\/author><\/authors><\/contributors><auth-address>From the Departments of Neurology and Epidemiology and Population Health&#x002C; Albert Einstein College of Medicine&#x002C; and Montefiore Medical Center - both in Bronx&#x002C; NY (R.B.L.); Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT (R.C.&#x002C; E.G.S.&#x002C; D.A.S.&#x002C; B.A.M.&#x002C; M.F.&#x002C; G.M.D.&#x002C; C.M.C.&#x002C; V.C.); NIHR-Wellcome Trust King&apos;s Clinical Research Facility&#x002C; King&apos;s College Hospital-South London and Maudsley Biomedical Research Centre&#x002C; King&apos;s College London&#x002C; London (P.J.G.); and the University of California&#x002C; San Francisco&#x002C; San Francisco (P.J.G.).<\/auth-address><titles><title>Rimegepant&#x002C; an oral calcitonin gene-related peptide receptor antagonist&#x002C; for migraine<\/title><secondary-title>N Engl J Med<\/secondary-title><\/titles><pages>142-149<\/pages><volume>381<\/volume><number>2<\/number><dates><year>2019<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31291516<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=19361.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1056\/NEJMoa1811090<\/electronic-resource-num><access-date>2019-08-15<\/access-date><modified-date>H\u00b0 Zen; H\u00b0 Pijn; TF Mig<\/modified-date><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>9<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]--><\/td>\n<td>Rim\u00e9g\u00e9pant<br \/> 75 mg vs. placebo<\/td>\n<td>Disparition de la douleur apr\u00e8s 2\u00a0h<br \/> (92% ont termin\u00e9 l&#39;\u00e9tude)<\/p>\n<p> Disparition du sympt\u00f4me le plus invalidant apr\u00e8s 2\u00a0h<\/td>\n<td>21&#x002C;2% contre 10&#x002C;9%<br \/> Diff\u00e9rence de 10&#x002C;4% (IC \u00e0 95% de 6&#x002C;5 \u00e0 14&#x002C;2)<\/p>\n<p> 35&#x002C;1% contre 26&#x002C;8%<br \/> Diff\u00e9rence de 8&#x002C;3% (IC \u00e0 95% de 3&#x002C;4 \u00e0 13&#x002C;2)<\/td>\n<\/tr>\n<tr>\n<td>RCT aupr\u00e8s de 1 162 adultes pr\u00e9sentant 2 \u00e0 8 crises de migraine par mois<sup><span class=&quot;folia-referentie-nummer&quot;>3<\/span><\/sup>&#x002C; <a href=&quot;https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03235479&quot;>BHV3000-301<\/a><br \/> (pas encore examin\u00e9e par des pairs)<\/td>\n<td>Rim\u00e9g\u00e9pant<br \/> 75 mg vs placebo<\/td>\n<td>Disparition de la douleur apr\u00e8s 2\u00a0h<br \/> (93% ont termin\u00e9 l&#39;\u00e9tude)<\/p>\n<p> Disparition du sympt\u00f4me le plus invalidant apr\u00e8s 2\u00a0h<\/td>\n<td>19&#x002C;2% contre 14&#x002C;2%<br \/> Diff\u00e9rence de 4&#x002C;9% (IC \u00e0 95% de 0&#x002C;5 \u00e0 9&#x002C;3)<\/p>\n<p> 36&#x002C;6% contre 27&#x002C;7%<br \/> Diff\u00e9rence de 8&#x002C;9% (IC \u00e0 95% de 3&#x002C;4 \u00e0 14&#x002C;4)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p> \u00a0 <\/p>\n<ul>\n<li>Une m\u00e9ta-analyse publi\u00e9e dans le JAMA<sup><span class=&quot;folia-referentie-nummer&quot;>11<\/span><\/sup> incluait uniquement des \u00e9tudes publi\u00e9es. Selon cette m\u00e9ta-analyse&#x002C; la probabilit\u00e9 d\u2019\u00eatre sans douleur apr\u00e8s deux heures \u00e9tait plus grande avec le rim\u00e9g\u00e9pant qu&#39;avec le placebo (RR 1&#x002C;80 (IC \u00e0 95% 1&#x002C;52 \u00e0 2&#x002C;13)&#x002C; diff\u00e9rence de risque de 0&#x002C;09 (IC \u00e0 95% de 0&#x002C;06 \u00e0 0&#x002C;11)&#x002C; niveau de preuve mod\u00e9r\u00e9).<\/li>\n<li>Un article de synth\u00e8se de Cohen<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height: 150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:FR-BE;mso-fareast-language:NL-BE; mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Cohen<\/Author><Year>2022<\/Year><RecNum>27249<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>6<\/style>\n\n<\/DisplayText><record><rec-number>27249<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>27249<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Cohen&#x002C;Fred<\/author><author>Yuan&#x002C;Hsiangkuo<\/author><author>Silberstein&#x002C;Stephen D<\/author><\/authors><\/contributors><auth-address>Jefferson Headache Center&#x002C; Department of Neurology&#x002C; Thomas Jefferson University&#x002C; 900 Walnut Street&#x002C; Suite 200&#x002C; Philadelphia&#x002C; PA&#x002C; 19107&#x002C; USA.<\/auth-address><titles><title>Calcitonin Gene-Related Peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale.<\/title><secondary-title>BioDrugs<\/secondary-title><\/titles><pages>341-358<\/pages><volume>36<\/volume><number>3<\/number><dates><year>2022<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35476215<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27249.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1007\/s40259-022-00530-0<\/electronic-resource-num><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>6<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]--> sur le rim\u00e9g\u00e9pant&#x002C; cit\u00e9 dans le <i>Geneesmiddelenbulletin<\/i><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height: 150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:FR-BE;mso-fareast-language:NL-BE; mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Schwarz<\/Author><Year>2022<\/Year><RecNum>26417<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>2<\/style>\n\n<\/DisplayText><record><rec-number>26417<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>26417<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Schwarz&#x002C;E. P. <\/author><\/authors><\/contributors><titles><title>Nieuw geneesmiddel: rimegepant bij migraineaanvallen<\/title><secondary-title>Geneesmiddelenbulletin<\/secondary-title><\/titles><pages>65-8<\/pages><volume>8<\/volume><dates><year>2022<\/year><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26417.pdf<\/url><\/pdf-urls><\/urls><access-date>2022\/08\/02 tot 2022\/08\/15<\/access-date><modified-date>H\u00b0 Psy; ISDB<\/modified-date><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>2<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->&#x002C; fait r\u00e9f\u00e9rence \u00e0 une autre m\u00e9ta-analyse<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height: 150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:FR-BE;mso-fareast-language:NL-BE; mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Gao<\/Author><Year>2020<\/Year><RecNum>27460<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>12<\/style>\n\n<\/DisplayText><record><rec-number>27460<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>27460<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Gao&#x002C;Bixi<\/author><author>Yang&#x002C;Yanbo<\/author><author>Wang&#x002C;Zilan<\/author><author>Sun&#x002C;Yue<\/author><author>Chen&#x002C;Zhouqing<\/author><author>Zhu&#x002C;Yun<\/author><author>Wang&#x002C;Zhong<\/author><\/authors><\/contributors><auth-address>Department of Neurosurgery & Brain and Nerve Research Laboratory&#x002C; The First Affiliated Hospital of Soochow University&#x002C; Suzhou&#x002C; China.<\/auth-address><titles><title>Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials.<\/title><secondary-title>Front Pharmacol<\/secondary-title><\/titles><pages>1577<\/pages><volume>10<\/volume><dates><year>2020<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32038251<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27460.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.3389\/fphar.2019.01577<\/electronic-resource-num><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>12<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->&#x002C; qui inclut \u00e9galement les donn\u00e9es d&#39;une \u00e9tude non publi\u00e9e. Les r\u00e9sultats de cette m\u00e9ta-analyse sont comparables aux r\u00e9sultats de la m\u00e9ta-analyse publi\u00e9e dans le JAMA.<\/li>\n<li>Selon <a href=&quot;https:\/\/www.minerva-ebp.be\/Home\/Glossary?alpha=m#glossaryId20&quot;>une m\u00e9ta-analyse en r\u00e9seau<\/a> portant uniquement sur des comparaisons indirectes<span class=&quot;folia-referentie-nummer&quot;><sup>8<\/sup><\/span>&#x002C; la plupart des triptans sont associ\u00e9s \u00e0 une plus grande probabilit\u00e9 de disparition des douleurs dans les deux heures que le rim\u00e9g\u00e9pant (rapport de cotes (odds ratio) de 1&#x002C;58 (IC \u00e0 95% de 1&#x002C;07 \u00e0 2&#x002C;33) \u00e0 3&#x002C;13 (IC \u00e0 95% de 2&#x002C;16 \u00e0 4&#x002C;52)). Mais les populations \u00e9tudi\u00e9es ne sont pas tout \u00e0 fait comparables. Une <em>Cochrane Review<\/em><span class=&quot;folia-referentie-nummer&quot;><sup>13<\/sup><\/span> nous apprend par exemple que la plupart des \u00e9tudes sur le sumatriptan oral incluaient des patients ayant en moyenne 1 \u00e0 6 crises par mois. Dans les \u00e9tudes sur le rim\u00e9g\u00e9pant&#x002C; les patients inclus avaient en moyenne 2 \u00e0 8 crises de migraine par mois.<\/li>\n<\/ul><\/div>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>On ne dispose pas encore d&#39;\u00e9tudes publi\u00e9es sur l&#39;efficacit\u00e9 et la s\u00e9curit\u00e9 du rim\u00e9g\u00e9pant <b>chez les patients ne r\u00e9pondant pas ou pr\u00e9sentant des contre-indications aux autres traitements de crise<\/b>. Le rim\u00e9g\u00e9pant pourrait \u00eatre une alternative pour les patients ne r\u00e9pondant pas aux triptans. Une \u00e9tude a toutefois \u00e9t\u00e9 lanc\u00e9e r\u00e9cemment pour \u00e9valuer l\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 du rim\u00e9g\u00e9pant chez des patients migraineux non \u00e9ligibles aux triptans [<a href=&quot;https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05509400&quot;>Clinicaltrials.gov<\/a>].<\/p>\n<\/li>\n<li>\n<p>On sait que les triptans et les antalgiques sont susceptibles de provoquer une aggravation de la migraine et des c\u00e9phal\u00e9es chroniques quotidiennes en cas de surconsommation<span class=&quot;folia-referentie-nummer&quot;><sup>14<\/sup><\/span>. \u00c0 l\u2019heure actuelle&#x002C; ce risque ne peut \u00eatre exclu pour le rim\u00e9g\u00e9pant en raison des donn\u00e9es insuffisantes.<\/p>\n<\/li>\n<\/ul>\n<h3>Les effets \u00e0 long terme du rim\u00e9g\u00e9pant en traitement de crise<\/h3>\n<ul>\n<li>\n<p>Toutes les \u00e9tudes randomis\u00e9es ayant \u00e9valu\u00e9 l&#39;effet du rim\u00e9g\u00e9pant en traitement de crise portaient sur une administration unique. La question est de savoir si l&#39;effet est maintenu lorsque le rim\u00e9g\u00e9pant est utilis\u00e9 de fa\u00e7on r\u00e9p\u00e9t\u00e9e dans les crises de migraine r\u00e9currentes<!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE;mso-fareast-language: NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283489\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Schwarz<\/Author><Year>2022<\/Year><RecNum>26417<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>2<\/style>\n\n<\/DisplayText><record><rec-number>26417<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>26417<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Schwarz&#x002C;E. P. <\/author><\/authors><\/contributors><titles><title>Nieuw geneesmiddel: rimegepant bij migraineaanvallen<\/title><secondary-title>Geneesmiddelenbulletin<\/secondary-title><\/titles><pages>65-8<\/pages><volume>8<\/volume><dates><year>2022<\/year><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26417.pdf<\/url><\/pdf-urls><\/urls><access-date>2022\/08\/02 tot 2022\/08\/15<\/access-date><modified-date>H\u00b0 Psy; ISDB<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>2<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<\/p>\n<\/li>\n<li>\n<p>Selon une <b>analyse <i>a posteriori<\/i> <\/b>des donn\u00e9es d&#39;une <b>\u00e9tude de s\u00e9curit\u00e9 ouverte<\/b>&#x002C; le rim\u00e9g\u00e9pant \u00e9tait toujours efficace apr\u00e8s un an&#x002C; utilis\u00e9 \u00ab\u00a0selon les besoins\u00a0\u00bb <!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height: 150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:FR-BE;mso-fareast-language:NL-BE; mso-bidi-language:AR-SA\u2019><span style=\u2019mso-spacerun:yes\u2019>\u00a0<\/span>ADDIN EN.CITE <\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height: 150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:FR-BE;mso-fareast-language:NL-BE; mso-bidi-language:AR-SA\u2019><span style=\u2019mso-spacerun:yes\u2019>\u00a0<\/span>ADDIN EN.CITE.DATA <\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family: &quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;; mso-ansi-language:NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><![if gte mso 9]><xml> <w:data>3C456E644E6F74653E3C436974653E3C417574686F723E436F68656E3C2F417574686F723E3C596561723E323032323C2F596561723E3C5265634E756D3E32373234393C2F5265634E756D3E3C446973706C6179546578743E3C7374796C6520666163653D227375706572736372697074223E362C2031353C2F7374796C653E3C2F446973706C6179546578743E3C7265636F72643E3C7265632D6E756D6265723E32373234393C2F7265632D6E756D6265723E3C666F726569676E2D6B6579733E3C6B6579206170703D22454E222064622D69643D2239657374776666726D643276736C657230663470613264653235667A7870723030357377222074696D657374616D703D2230223E32373234393C2F6B65793E3C2F666F726569676E2D6B6579733E3C7265662D74797065206E616D653D224A6F75726E616C2041727469636C65223E31373C2F7265662D747970653E3C636F6E7472696275746F72733E3C617574686F72733E3C617574686F723E436F68656E2C467265643C2F617574686F723E3C617574686F723E5975616E2C487369616E676B756F3C2F617574686F723E3C617574686F723E53696C626572737465696E2C5374657068656E20443C2F617574686F723E3C2F617574686F72733E3C2F636F6E7472696275746F72733E3C617574682D616464726573733E4A6566666572736F6E2048656164616368652043656E7465722C204465706172746D656E74206F66204E6575726F6C6F67792C2054686F6D6173204A6566666572736F6E20556E69766572736974792C203930302057616C6E7574205374726565742C205375697465203230302C205068696C6164656C706869612C2050412C2031393130372C205553412E3C2F617574682D616464726573733E3C7469746C65733E3C7469746C653E43616C6369746F6E696E2047656E652D52656C617465642050657074696465202843475250292D7461726765746564206D6F6E6F636C6F6E616C20616E7469626F6469657320616E6420616E7461676F6E6973747320696E206D69677261696E653A2063757272656E742065766964656E636520616E6420726174696F6E616C652E3C2F7469746C653E3C7365636F6E646172792D7469746C653E42696F44727567733C2F7365636F6E646172792D7469746C653E3C2F7469746C65733E3C70616765733E3334312D3335383C2F70616765733E3C766F6C756D653E33363C2F766F6C756D653E3C6E756D6265723E333C2F6E756D6265723E3C64617465733E3C796561723E323032323C2F796561723E3C2F64617465733E3C75726C733E3C72656C617465642D75726C733E3C75726C3E68747470733A2F2F7777772E6E6362692E6E6C6D2E6E69682E676F762F7075626D65642F33353437363231353C2F75726C3E3C2F72656C617465642D75726C733E3C7064662D75726C733E3C75726C3E68747470733A2F2F6C69622E626366692D636269702E62652F6C696272617269616E2F7064667669657765722E7068703F66696C653D32373234392E7064663C2F75726C3E3C2F7064662D75726C733E3C2F75726C733E3C656C656374726F6E69632D7265736F757263652D6E756D3E31302E313030372F7334303235392D3032322D30303533302D303C2F656C656374726F6E69632D7265736F757263652D6E756D3E3C2F7265636F72643E3C2F436974653E3C436974653E3C417574686F723E4A6F686E73746F6E3C2F417574686F723E3C596561723E323032323C2F596561723E3C5265634E756D3E32373235333C2F5265634E756D3E3C7265636F72643E3C7265632D6E756D6265723E32373235333C2F7265632D6E756D6265723E3C666F726569676E2D6B6579733E3C6B6579206170703D22454E222064622D69643D2239657374776666726D643276736C657230663470613264653235667A7870723030357377222074696D657374616D703D2230223E32373235333C2F6B65793E3C2F666F726569676E2D6B6579733E3C7265662D74797065206E616D653D224A6F75726E616C2041727469636C65223E31373C2F7265662D747970653E3C636F6E7472696275746F72733E3C617574686F72733E3C617574686F723E4A6F686E73746F6E2C4B6172697373613C2F617574686F723E3C617574686F723E4861727269732C4C696E64613C2F617574686F723E3C617574686F723E506F77656C6C2C4C617572656E3C2F617574686F723E3C617574686F723E506F706F66662C4576616E3C2F617574686F723E3C617574686F723E436F7269632C566C6164696D69723C2F617574686F723E3C617574686F723E4C4974616C69656E2C47696C626572743C2F617574686F723E3C617574686F723E5363687265696265722C43757274697320503C2F617574686F723E3C2F617574686F72733E3C2F636F6E7472696275746F72733E3C617574682D616464726573733E42726F6164737472656574204865616C74682045636F6E6F6D6963732026616D703B204F7574636F6D65732052657365617263682C2056616E636F757665722C2042432C2043616E6164612E206B6A6F686E73746F6E4062726F616473747265657468656F722E636F6D2E3C2F617574682D616464726573733E3C7469746C65733E3C7469746C653E4D6F6E74686C79206D69677261696E6520646179732C207461626C6574207574696C697A6174696F6E2C20616E64207175616C697479206F66206C696665206173736F63696174656420776974682052696D65676570616E74202D20706F737420686F6320726573756C74732066726F6D20616E206F70656E206C6162656C207361666574792073747564792028424856333030302D323031292E3C2F7469746C653E3C7365636F6E646172792D7469746C653E4A204865616461636865205061696E3C2F7365636F6E646172792D7469746C653E3C2F7469746C65733E3C70616765733E31303C2F70616765733E3C766F6C756D653E32333C2F766F6C756D653E3C6E756D6265723E313C2F6E756D6265723E3C64617465733E3C796561723E323032323C2F796561723E3C2F64617465733E3C75726C733E3C72656C617465642D75726C733E3C75726C3E68747470733A2F2F7777772E6E6362692E6E6C6D2E6E69682E676F762F7075626D65642F33353033383938333C2F75726C3E3C2F72656C617465642D75726C733E3C7064662D75726C733E3C75726C3E68747470733A2F2F6C69622E626366692D636269702E62652F6C696272617269616E2F7064667669657765722E7068703F66696C653D32373235332E7064663C2F75726C3E3C2F7064662D75726C733E3C2F75726C733E3C656C656374726F6E69632D7265736F757263652D6E756D3E31302E313138362F7331303139342D3032312D30313337382D353C2F656C656374726F6E69632D7265736F757263652D6E756D3E3C2F7265636F72643E3C2F436974653E3C2F456E644E6F74653E00<\/w:data> <\/xml><![endif]><span style=\u2019mso-element:field-end\u2019><\/span><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>6&#x002C; 15<\/sup><\/span><!--[if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]--><!--[if supportFields]><span style=\u2019font-size:12.0pt; line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:NL-BE;mso-fareast-language:NL-BE; mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->. L\u2019\u00e9tude avait toutefois un taux d\u2019abandon \u00e9lev\u00e9 (environ 4 patients sur 10&#x002C; raison non pr\u00e9cis\u00e9e)&#x002C; ce qui complique l&#39;interpr\u00e9tation des r\u00e9sultats. Des recherches suppl\u00e9mentaires sont n\u00e9cessaires.<br \/> \u00a0<\/p>\n<\/li>\n<\/ul>\n<h2>Efficacit\u00e9 du rim\u00e9g\u00e9pant en prophylaxie antimigraineuse<\/h2>\n<div class=&quot;summary&quot;>Les patients ayant en moyenne 10 jours de migraine par mois&#x002C; ont en moyenne 0&#x002C;8 jours de migraine en moins au cours du troisi\u00e8me mois suivant le d\u00e9but de la prise prophylactique de rim\u00e9g\u00e9pant (tous les deux jours)&#x002C; par rapport au placebo.<br \/> Pr\u00e8s de la moiti\u00e9 des patients rapportent une r\u00e9duction d&#39;au moins 50% du nombre de jours de migraine mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re par mois avec le rim\u00e9g\u00e9pant&#x002C; contre 41% patients avec le placebo. On ignore actuellement si le b\u00e9n\u00e9fice est maintenu en cas de traitement durant plus de 3 mois.<br \/> \u200bDes \u00e9tudes comparatives directes avec d&#39;autres antimigraineux prophylactiques sont n\u00e9cessaires pour mieux cerner la place du rim\u00e9g\u00e9pant au sein de l&#39;arsenal th\u00e9rapeutique. Des \u00e9tudes sont \u00e9galement n\u00e9cessaires pour \u00e9valuer l&#39;utilit\u00e9 d\u2019une prophylaxie au rim\u00e9g\u00e9pant chez les patients ayant \u00e9chou\u00e9 \u00e0 d&#39;autres traitements prophylactiques antimigraineux.<\/div>\n<h3>Le rim\u00e9g\u00e9pant en prophylaxie compar\u00e9 au placebo<\/h3>\n<ul>\n<li>\n<p>Dans une \u00e9tude randomis\u00e9e<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height: 150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:FR-BE;mso-fareast-language:EN-US; mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Croop<\/Author><Year>2021<\/Year><RecNum>22563<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>16<\/style>\n\n<\/DisplayText><record><rec-number>22563<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>22563<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Croop&#x002C;R. <\/author><author>Lipton&#x002C;R. B. <\/author><author>Kudrow&#x002C;D. <\/author><author>Stock&#x002C;D. A. <\/author><author>Kamen&#x002C;L. <\/author><author>Conway&#x002C;C. M. <\/author><author>Stock&#x002C;E. G. <\/author><author>Coric&#x002C;V. <\/author><author>Goadsby&#x002C;P. J. <\/author><\/authors><\/contributors><auth-address>Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. Electronic address: robert.croop@biohavenpharma.com. Department of Neurology&#x002C; Albert Einstein College of Medicine&#x002C; Bronx&#x002C; NY&#x002C; USA. California Medical Clinic for Headache&#x002C; Santa Monica&#x002C; CA&#x002C; USA. Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. NIHR-Wellcome Trust King&apos;s Clinical Research Facility&#x002C; King&apos;s College Hospital\/SLaM Biomedical Research Centre&#x002C; King&apos;s College London&#x002C; UK; University of California&#x002C; Los Angeles&#x002C; Los Angeles&#x002C; CA&#x002C; USA.<\/auth-address><titles><title>Oral rimegepant for preventive treatment of migraine: a phase 2\/3&#x002C; randomised&#x002C; double-blind&#x002C; placebo-controlled trial<\/title><secondary-title>Lancet<\/secondary-title><\/titles><pages>51-60<\/pages><volume>397<\/volume><number>10268<\/number><dates><year>2021<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33338437<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=22563.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1016\/S0140-6736(20)32544-7<\/electronic-resource-num><access-date>2021\/01\/02 tot 2021\/01\/15<\/access-date><modified-date>H\u00b0 Zen; TF Mig<\/modified-date><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>16<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->&#x002C; la <b>prise prophylactique <\/b>de rim\u00e9g\u00e9pant 75 mg (tous les deux jours) par des patients <b>migraineux <\/b>(83% de femmes&#x002C; \u00e2ge moyen de 41 ans&#x002C; en moyenne 10\u00a0jours de migraine par mois \u00e0 l\u2019inclusion) a entra\u00een\u00e9 une diminution des jours de migraine d\u2019en moyenne 0&#x002C;8 jour dans le troisi\u00e8me mois suivant le d\u00e9but de la prise&#x002C; par rapport au placebo. Avec le rim\u00e9g\u00e9pant&#x002C; le nombre de jours de migraine avait diminu\u00e9 en moyenne de 4&#x002C;3&#x002C; contre 3&#x002C;5 jours en moyenne avec le placebo. Le nombre de jours de migraine mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re par mois avait diminu\u00e9 d&#39;au moins la moiti\u00e9 chez 49% des patients&#x002C; contre 41% des patients sous placebo.<\/p>\n<\/li>\n<li>\n<p>L\u2019\u00e9tude incluait trop peu de patients souffrant de migraine chronique pour pouvoir se prononcer sur l&#39;effet du rim\u00e9g\u00e9pant dans ce sous-groupe. C\u2019est pourquoi l&#39;indication dans le RCP a \u00e9t\u00e9 limit\u00e9e \u00e0 la <b>migraine \u00e9pisodique<\/b>.<\/p>\n<\/li>\n<li>\n<p>Il n&#39;existe pas de donn\u00e9es sur l&#39;efficacit\u00e9 du <b>rim\u00e9g\u00e9pant utilis\u00e9 en aigu<\/b> chez les patients qui en prennent d\u00e9j\u00e0 \u00e0 titre prophylactique. Dans l&#39;\u00e9tude sur la prophylaxie&#x002C; le recours au rim\u00e9g\u00e9pant en traitement de crise n&#39;\u00e9tait pas autoris\u00e9.<\/p>\n<\/li>\n<li>\n<p><er de=&quot;&quot; geen=&quot;&quot; gegevens=&quot;&quot; over=&quot;&quot; van=&quot;&quot; werkzaamheid=&quot;&quot; zijn=&quot;&quot;>R\u00e9cemment&#x002C;\u00a0une RCT a \u00e9t\u00e9 lanc\u00e9e pour \u00e9valuer le rim\u00e9g\u00e9pant chez des <strong><a href=&quot;https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05518123&quot;>patients n\u2019ayant pas r\u00e9pondu \u00e0 d&#39;autres traitements prophylactiques <\/a>antimigraineux par voie orale<\/strong>.<\/er><\/p>\n<\/li>\n<\/ul>\n<div class=&quot;detailed-content&quot;>L&#39;\u00e9tude ayant \u00e9valu\u00e9 le rim\u00e9g\u00e9pant en prophylaxie incluait des adultes souffrant de migraine avec aura (40%) ou sans aura (60%). 23% des participants avaient des ant\u00e9c\u00e9dents de migraine chronique.<br \/> Les patients devaient avoir au moins 4 et maximum 18 crises de migraine mod\u00e9r\u00e9es \u00e0 s\u00e9v\u00e8res par mois et avoir connu au moins 6 jours de migraine dans le mois pr\u00e9c\u00e9dant la randomisation.<\/p>\n<p> Tableau : \u00e9tudes randomis\u00e9es avec le rim\u00e9g\u00e9pant en prophylaxie antimigraineuse<br \/> \u00a0 <\/p>\n<table border=&quot;1&quot; cellpadding=&quot;1&quot; cellspacing=&quot;1&quot; style=&quot;width:600px;&quot;>\n<tbody>\n<tr>\n<td>\u00c9tude<\/td>\n<td>Interventions<\/td>\n<td>Crit\u00e8res d&#39;\u00e9valuation cliniques<\/td>\n<td>R\u00e9sultats<\/td>\n<\/tr>\n<tr>\n<td>RCT aupr\u00e8s de 747 adultes ayant en moyenne 10\u00a0jours de migraine par mois<span class=&quot;folia-referentie-nummer&quot;><sup>16<\/sup><\/span><\/td>\n<td>Rim\u00e9g\u00e9pant 75 mg tous les deux jours vs. placebo<\/p>\n<p> Dur\u00e9e du traitement: 3\u00a0mois (84% ont termin\u00e9 le traitement&#x002C; 93% ont \u00e9t\u00e9 inclus dans l&#39;analyse pour le crit\u00e8re d\u2019\u00e9valuation primaire)<\/td>\n<td>Variation du nombre de jours de migraine par mois (crit\u00e8re d\u2019\u00e9valuation primaire)<\/p>\n<p> Pourcentage de patients pr\u00e9sentant une r\u00e9duction d&#39;au moins 50% du nombre de jours de migraine mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re (crit\u00e8re d&#39;\u00e9valuation secondaire).<\/td>\n<td>-4&#x002C;3 contre -3&#x002C;5 jours<br \/> Diff\u00e9rence de -0&#x002C;8 jours (IC \u00e0 95% de -1&#x002C;46 \u00e0 -0&#x002C;20)<\/p>\n<p> 49% contre 41%<br \/> Diff\u00e9rence de 8%<br \/> (IC \u00e0 95% de 0 \u00e0 15&#x002C; p=0&#x002C;044)<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<h3>Le rim\u00e9g\u00e9pant compar\u00e9 \u00e0 d&#39;autres traitements prophylactiques de la migraine<\/h3>\n<ul>\n<li>\n<p>L&#39;effet du rim\u00e9g\u00e9pant semble \u00eatre du m\u00eame ordre de grandeur que celui d\u2019<strong>autres traitements prophylactiques de la migraine<\/strong>&#x002C; mais les populations ne sont pas toujours comparables (notamment en ce qui concerne le nombre de crises de migraine par mois). Des \u00e9tudes randomis\u00e9es comparatives directes sont n\u00e9cessaires pour d\u00e9finir la place du rim\u00e9g\u00e9pant au sein de l&#39;arsenal th\u00e9rapeutique pour la prophylaxie antimigraineuse. Sa forme d&#39;administration orale pourrait repr\u00e9senter un avantage par rapport aux anticorps monoclonaux&#x002C; mais ceci n\u2019a pas fait l\u2019objet d\u2019\u00e9tudes randomis\u00e9es comparatives. Une \u00e9tude comparative avec le galcan\u00e9zumab est en cours (<a href=&quot;https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05127486&quot;>CHALLENGE-MIG<\/a>)<sup><span class=&quot;folia-referentie-nummer&quot;>6<\/span><\/sup>.<\/p>\n<\/li>\n<\/ul>\n<h3>Les effets \u00e0 long terme du rim\u00e9g\u00e9pant en prophylaxie antimigraineuse<\/h3>\n<ul>\n<li>\n<p>L\u2019\u00e9tude en question ne durait que trois mois&#x002C; ce qui est tr\u00e8s court pour se prononcer sur l&#39;utilit\u00e9 du rim\u00e9g\u00e9pant en prophylaxie antimigraineuse. Nous n&#39;avons trouv\u00e9 aucune \u00e9tude publi\u00e9e ayant \u00e9valu\u00e9 le rim\u00e9g\u00e9pant sur une p\u00e9riode de suivi plus longue.<br \/> \u00a0<\/p>\n<\/li>\n<\/ul>\n<h2>Profil d\u2019innocuit\u00e9 du rim\u00e9g\u00e9pant<\/h2>\n<div class=&quot;summary&quot;>Le rim\u00e9g\u00e9pant semble bien tol\u00e9r\u00e9 dans les \u00e9tudes randomis\u00e9es. Des r\u00e9actions d&#39;hypersensibilit\u00e9 s\u00e9v\u00e8res peuvent survenir lorsqu\u2019il est utilis\u00e9 en aigu. Il faut attendre les r\u00e9sultats d\u2019\u00e9tudes post-commercialisation pour pouvoir \u00e9valuer la s\u00e9curit\u00e9 d&#39;utilisation \u00e0 long terme (plus de 3 mois)&#x002C; en particulier chez les patients \u00e0 risque cardiovasculaire&#x002C; en raison du risque th\u00e9orique d&#39;un effet vasoconstricteur associ\u00e9 aux inhibiteurs du CGRP. La co-administration du rim\u00e9g\u00e9pant avec d&#39;autres inhibiteurs du CGRP ou avec un triptan doit \u00e9galement \u00eatre mieux document\u00e9e en termes de s\u00e9curit\u00e9.<\/div>\n<ul>\n<li>\n<p>Dans les \u00e9tudes randomis\u00e9es ayant \u00e9valu\u00e9 le rim\u00e9g\u00e9pant en <b>traitement de crise&#x002C; <\/b>le rim\u00e9g\u00e9pant \u00e9tait bien tol\u00e9r\u00e9 : 10&#x002C;8% des patients ont pr\u00e9sent\u00e9 des effets ind\u00e9sirables suite \u00e0 une prise unique de rim\u00e9g\u00e9pant&#x002C; contre 8&#x002C;6% avec le placebo<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: FR-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>EMA<\/Author><RecNum>26646<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>3<\/style>\n\n<\/DisplayText><record><rec-number>26646<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>26646<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>EMA&#x002C;<\/author><\/authors><\/contributors><titles><title>EPAR-Assessment Report Vydura\u00ae<\/title><\/titles><dates><\/dates><urls><related-urls><url>https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vydura<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26646.pdf<\/url><\/pdf-urls><\/urls><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>3<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->. Les effets ind\u00e9sirables les plus fr\u00e9quemment rapport\u00e9s \u00e9taient\u00a0: naus\u00e9es (1&#x002C;2% contre 0&#x002C;8% avec le placebo) et infections des voies urinaires (0&#x002C;8% contre 0&#x002C;3% avec le placebo).<\/p>\n<\/li>\n<li>\n<p>La s\u00e9curit\u00e9 du <b>traitement prophylactique <\/b>est encore peu document\u00e9e pour l\u2019instant. La seule \u00e9tude randomis\u00e9e disponible<!--[if supportFields]><span style=\u2019font-size:12.0pt; line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font: minor-latin;color:#222222;mso-ansi-language:NL-BE;mso-fareast-language:NL-BE; mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: FR-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Croop<\/Author><Year>2021<\/Year><RecNum>22563<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>16<\/style>\n\n<\/DisplayText><record><rec-number>22563<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>22563<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Croop&#x002C;R. <\/author><author>Lipton&#x002C;R. B. <\/author><author>Kudrow&#x002C;D. <\/author><author>Stock&#x002C;D. A. <\/author><author>Kamen&#x002C;L. <\/author><author>Conway&#x002C;C. M. <\/author><author>Stock&#x002C;E. G. <\/author><author>Coric&#x002C;V. <\/author><author>Goadsby&#x002C;P. J. <\/author><\/authors><\/contributors><auth-address>Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. Electronic address: robert.croop@biohavenpharma.com. Department of Neurology&#x002C; Albert Einstein College of Medicine&#x002C; Bronx&#x002C; NY&#x002C; USA. California Medical Clinic for Headache&#x002C; Santa Monica&#x002C; CA&#x002C; USA. Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. NIHR-Wellcome Trust King&apos;s Clinical Research Facility&#x002C; King&apos;s College Hospital\/SLaM Biomedical Research Centre&#x002C; King&apos;s College London&#x002C; UK; University of California&#x002C; Los Angeles&#x002C; Los Angeles&#x002C; CA&#x002C; USA.<\/auth-address><titles><title>Oral rimegepant for preventive treatment of migraine: a phase 2\/3&#x002C; randomised&#x002C; double-blind&#x002C; placebo-controlled trial<\/title><secondary-title>Lancet<\/secondary-title><\/titles><pages>51-60<\/pages><volume>397<\/volume><number>10268<\/number><dates><year>2021<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33338437<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=22563.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1016\/S0140-6736(20)32544-7<\/electronic-resource-num><access-date>2021\/01\/02 tot 2021\/01\/15<\/access-date><modified-date>H\u00b0 Zen; TF Mig<\/modified-date><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>16<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]--> ne durait que 3\u00a0mois et n&#39;a montr\u00e9 aucune diff\u00e9rence entre le rim\u00e9g\u00e9pant et le placebo en ce qui concerne la survenue d\u2019effets ind\u00e9sirables (36% des patients dans les deux groupes).<\/p>\n<\/li>\n<li>\n<p>Les donn\u00e9es issues des \u00e9tudes randomis\u00e9es sont insuffisantes pour se prononcer sur le risque d&#39;<b>effets ind\u00e9sirables graves <\/b>avec le rim\u00e9g\u00e9pant en traitement de crise<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height: 150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font: minor-latin;color:#222222;mso-ansi-language:NL-BE;mso-fareast-language:NL-BE; mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: FR-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Halker Singh<\/Author><Year>2020<\/Year><RecNum>27247<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>17<\/style>\n\n<\/DisplayText><record><rec-number>27247<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>27247<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Halker Singh&#x002C;Rashmi<\/author><author>VanderPluym&#x002C;Juliana H. <\/author><author>Morrow&#x002C;Allison S. <\/author><author>Urtecho&#x002C;Meritxell<\/author><author>Nayfeh&#x002C;Tarek<\/author><author>et al&#x002C;<\/author><\/authors><\/contributors><titles><title>Acute treatments for episodic migraine. Comparative Effectiveness Review. Number 239<\/title><secondary-title>AHRQ<\/secondary-title><\/titles><volume>December<\/volume><dates><year>2020<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK566246\/<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27247.pdf<\/url><\/pdf-urls><\/urls><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>17<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->. Dans l&#39;\u00e9tude ayant \u00e9valu\u00e9 le traitement prophylactique<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: FR-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Croop<\/Author><Year>2021<\/Year><RecNum>22563<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>16<\/style>\n\n<\/DisplayText><record><rec-number>22563<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>22563<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Croop&#x002C;R. <\/author><author>Lipton&#x002C;R. B. <\/author><author>Kudrow&#x002C;D. <\/author><author>Stock&#x002C;D. A. <\/author><author>Kamen&#x002C;L. <\/author><author>Conway&#x002C;C. M. <\/author><author>Stock&#x002C;E. G. <\/author><author>Coric&#x002C;V. <\/author><author>Goadsby&#x002C;P. J. <\/author><\/authors><\/contributors><auth-address>Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. Electronic address: robert.croop@biohavenpharma.com. Department of Neurology&#x002C; Albert Einstein College of Medicine&#x002C; Bronx&#x002C; NY&#x002C; USA. California Medical Clinic for Headache&#x002C; Santa Monica&#x002C; CA&#x002C; USA. Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. NIHR-Wellcome Trust King&apos;s Clinical Research Facility&#x002C; King&apos;s College Hospital\/SLaM Biomedical Research Centre&#x002C; King&apos;s College London&#x002C; UK; University of California&#x002C; Los Angeles&#x002C; Los Angeles&#x002C; CA&#x002C; USA.<\/auth-address><titles><title>Oral rimegepant for preventive treatment of migraine: a phase 2\/3&#x002C; randomised&#x002C; double-blind&#x002C; placebo-controlled trial<\/title><secondary-title>Lancet<\/secondary-title><\/titles><pages>51-60<\/pages><volume>397<\/volume><number>10268<\/number><dates><year>2021<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33338437<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=22563.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1016\/S0140-6736(20)32544-7<\/electronic-resource-num><access-date>2021\/01\/02 tot 2021\/01\/15<\/access-date><modified-date>H\u00b0 Zen; TF Mig<\/modified-date><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>16<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->&#x002C; la fr\u00e9quence d\u2019apparition des effets ind\u00e9sirables graves \u00e9tait similaire pour le rim\u00e9g\u00e9pant et le placebo (1%). Des \u00e9tudes \u00e0 plus grande \u00e9chelle sont n\u00e9cessaires pour le confirmer.<\/p>\n<\/li>\n<li>\n<p>L\u2019effet apr\u00e8s l&#39;<b>arr\u00eat du traitement<\/b> ou le ph\u00e9non\u00e8me de rebond (augmentation du nombre de crises de migraine) en cas d\u2019arr\u00eat brutal n\u2019ont pas \u00e9t\u00e9 \u00e9tudi\u00e9s. Aucun indice de rebond n\u2019a \u00e9t\u00e9 identifi\u00e9 dans les \u00e9tudes disponibles. Aucun signal sugg\u00e9rant <b>une<\/b> <b>surconsommation ou un m\u00e9susage<\/b> de rim\u00e9gepant n&#39;a \u00e9t\u00e9 rapport\u00e9 lors d&#39;une administration \u00e0 long terme<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: FR-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>EMA<\/Author><RecNum>26646<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>3<\/style>\n\n<\/DisplayText><record><rec-number>26646<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>26646<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>EMA&#x002C;<\/author><\/authors><\/contributors><titles><title>EPAR-Assessment Report Vydura\u00ae<\/title><\/titles><dates><\/dates><urls><related-urls><url>https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vydura<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26646.pdf<\/url><\/pdf-urls><\/urls><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>3<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->. Ces questions doivent faire l&#39;objet d&#39;un suivi plus approfondi dans le cadre d&#39;\u00e9tudes post-commercialisation.<\/p>\n<\/li>\n<li>\n<p>Des <b>r\u00e9actions d&#39;hypersensibilit\u00e9<\/b>&#x002C; incluant dyspn\u00e9e et \u00e9ruption cutan\u00e9e s\u00e9v\u00e8re&#x002C; peuvent survenir plusieurs jours apr\u00e8s l&#39;administration. Elles sont survenues chez moins de 1% des patients dans les \u00e9tudes cliniques<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span> ADDIN EN.CITE <EndNote><Cite><RecNum>26645<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>18<\/style>\n\n<\/DisplayText><record><rec-number>26645<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>26645<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><\/contributors><titles><title>Vydura\u00ae - Samenvatting van de Kenmerken van het Product<\/title><\/titles><dates><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26645.pdf<\/url><\/pdf-urls><\/urls><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>18<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<\/p>\n<\/li>\n<li>\n<p>Contrairement aux triptans&#x002C; le rim\u00e9g\u00e9pant n&#39;est pas contre-indiqu\u00e9 en cas de <b>maladie cardiovasculaire<\/b><!--[if supportFields]><span style=\u2019font-size:12.0pt; line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:NL-BE;mso-fareast-language:EN-US; mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:FR-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Schwarz<\/Author><Year>2022<\/Year><RecNum>26417<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>2<\/style>\n\n<\/DisplayText><record><rec-number>26417<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>26417<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Schwarz&#x002C;E. P. <\/author><\/authors><\/contributors><titles><title>Nieuw geneesmiddel: rimegepant bij migraineaanvallen<\/title><secondary-title>Geneesmiddelenbulletin<\/secondary-title><\/titles><pages>65-8<\/pages><volume>8<\/volume><dates><year>2022<\/year><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26417.pdf<\/url><\/pdf-urls><\/urls><access-date>2022\/08\/02 tot 2022\/08\/15<\/access-date><modified-date>H\u00b0 Psy; ISDB<\/modified-date><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>2<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->. \u00c9tant donn\u00e9 que les \u00e9tudes ont exclu les patients pr\u00e9sentant une maladie cardiovasculaire non contr\u00f4l\u00e9e&#x002C; instable&#x002C; r\u00e9cemment diagnostiqu\u00e9e ou s\u00e9v\u00e8re&#x002C; la s\u00e9curit\u00e9 d\u2019utilisation dans cette population reste toutefois incertaine<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height: 150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:FR-BE;mso-fareast-language:EN-US; mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>EMA<\/Author><RecNum>26646<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>3<\/style>\n\n<\/DisplayText><record><rec-number>26646<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>26646<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>EMA&#x002C;<\/author><\/authors><\/contributors><titles><title>EPAR-Assessment Report Vydura\u00ae<\/title><\/titles><dates><\/dates><urls><related-urls><url>https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vydura<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26646.pdf<\/url><\/pdf-urls><\/urls><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>3<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<\/p>\n<\/li>\n<li>\n<p>Il n&#39;est pas possible de se prononcer sur la s\u00e9curit\u00e9 de l&#39;utilisation combin\u00e9e de rim\u00e9g\u00e9pant et de <b>triptans<\/b> en raison du manque de donn\u00e9es. Dans les \u00e9tudes sur le rim\u00e9g\u00e9pant en traitement de crise&#x002C; les triptans n&#39;\u00e9taient pas autoris\u00e9s dans les 48 heures suivant la prise de rim\u00e9g\u00e9pant. Dans l&#39;\u00e9tude sur le rim\u00e9g\u00e9pant en prophylaxie antimigraineuse&#x002C; les triptans \u00e9taient autoris\u00e9s&#x002C; mais les auteurs ne mentionnent pas \u00e0 quelle fr\u00e9quence ils ont \u00e9t\u00e9 pris (dans le groupe rim\u00e9g\u00e9pant&#x002C; des \u00ab\u00a0m\u00e9dicaments de secours\u00a0\u00bb\u00a0(rescue) ont \u00e9t\u00e9 utilis\u00e9s pendant 3&#x002C;7 jours au cours du dernier mois de l&#39;\u00e9tude&#x002C; contre 4 jours dans le groupe placebo&#x002C; une diff\u00e9rence qui n\u2019\u00e9tait pas statistiquement significative).<\/p>\n<\/li>\n<li>\n<p>Concernant l&#39;utilisation concomitante du rim\u00e9g\u00e9pant avec des <b>anticorps monoclonaux <\/b>en prophylaxie antimigraineuse&#x002C; les donn\u00e9es disponibles sont rassurantes mais elles sont trop limit\u00e9es et de trop courte dur\u00e9e pour pouvoir se prononcer sur la s\u00e9curit\u00e9 d\u2019une telle utilisation<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><\/span><span lang=FR-BE style=\u2019font-size:12.0pt;line-height: 150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: &quot;Times New Roman&quot;;mso-ansi-language:FR-BE;mso-fareast-language:EN-US; mso-bidi-language:AR-SA\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Cohen<\/Author><Year>2022<\/Year><RecNum>27249<\/RecNum><DisplayText>\n\n<style face=&quot;superscript&quot;>6<\/style>\n\n<\/DisplayText><record><rec-number>27249<\/rec-number><foreign-keys><key app=&quot;EN&quot; db-id=&quot;9estwffrmd2vsler0f4pa2de25fzxpr005sw&quot; timestamp=&quot;0&quot;>27249<\/key><\/foreign-keys><ref-type name=&quot;Journal Article&quot;>17<\/ref-type><contributors><authors><author>Cohen&#x002C;Fred<\/author><author>Yuan&#x002C;Hsiangkuo<\/author><author>Silberstein&#x002C;Stephen D<\/author><\/authors><\/contributors><auth-address>Jefferson Headache Center&#x002C; Department of Neurology&#x002C; Thomas Jefferson University&#x002C; 900 Walnut Street&#x002C; Suite 200&#x002C; Philadelphia&#x002C; PA&#x002C; 19107&#x002C; USA.<\/auth-address><titles><title>Calcitonin Gene-Related Peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale.<\/title><secondary-title>BioDrugs<\/secondary-title><\/titles><pages>341-358<\/pages><volume>36<\/volume><number>3<\/number><dates><year>2022<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35476215<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27249.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1007\/s40259-022-00530-0<\/electronic-resource-num><\/record><\/Cite><\/EndNote><\/span><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-separator\u2019><\/span><\/span><![endif]--><span class=&quot;folia-referentie-nummer&quot;><sup>6<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:&quot;Calibri&quot;&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->. La prudence s&#39;impose car le CGRP est impliqu\u00e9 dans plusieurs processus physiologiques et l&#39;association d\u2019inhibiteurs du CGRP pourrait th\u00e9oriquement entra\u00eener une hypertension ou des accidents isch\u00e9miques. Des \u00e9tudes \u00e0 long terme sur des populations plus importantes sont n\u00e9cessaires pour d\u00e9terminer dans quels sous-groupes la th\u00e9rapie combin\u00e9e peut repr\u00e9senter un b\u00e9n\u00e9fice et dans quels sous-groupes elle peut au contraire exposer \u00e0 des risques suppl\u00e9mentaires.<span class=&quot;folia-referentie-note&quot;>19<\/span><\/p>\n<\/li>\n<li>\n<p>L\u2019utilisation du rim\u00e9g\u00e9pant pendant la <b>grossesse <\/b>n\u2019est pas suffisamment document\u00e9e. Par mesure de pr\u00e9caution&#x002C; le rim\u00e9g\u00e9pant est d\u00e9conseill\u00e9.<\/p>\n<\/li>\n<li>\n<p><b>Interactions\u00a0<\/b>: le rim\u00e9g\u00e9pant est un substrat du CYP3A4 et de la P-gp. La co-administration avec des inhibiteurs puissants du CYP3A4 ou avec des inducteurs puissants ou mod\u00e9r\u00e9s du CYP3A4 n&#39;est pas recommand\u00e9e. En cas d&#39;utilisation concomitante d&#39;inhibiteurs mod\u00e9r\u00e9s du CYP3A4 ou d&#39;inhibiteurs puissants de la P-gp&#x002C; il faut \u00e9viter la prise d&#39;une 2<sup>e<\/sup> dose de rim\u00e9g\u00e9pant dans les 48\u00a0heures (voir Tableau Ic et Tableau Id dans <a href=&quot;https:\/\/www.cbip.be\/fr\/chapters\/1?frag=9990243&quot;>l&#39;Introduction 6.3<\/a>).<\/p>\n<\/li>\n<li>\n<p><b>Pr\u00e9cautions particuli\u00e8res <\/b>: le rim\u00e9g\u00e9pant doit \u00eatre \u00e9vit\u00e9 chez les patients pr\u00e9sentant une insuffisance h\u00e9patique s\u00e9v\u00e8re<br \/> \u00a0<\/p>\n<\/li>\n<\/ul>\n<h2>Commentaires du CBIP<\/h2>\n<ul>\n<li>\n<p>Nos messages concernant le rim\u00e9g\u00e9pant rejoignent en grande partie ceux que nous avions donn\u00e9s au sujet des anticorps monoclonaux dans la migraine [voir <a href=&quot;https:\/\/www.cbip.be\/fr\/articles\/3662?folia=3658&quot;>Folia d\u2019ao\u00fbt 2021<\/a>]. Il est probable que ce nouveau m\u00e9dicament aura un int\u00e9r\u00eat chez certains patients&#x002C; mais les caract\u00e9ristiques qui distinguent les \u00ab\u00a0r\u00e9pondeurs\u00a0\u00bb des \u00ab\u00a0non-r\u00e9pondeurs\u00a0\u00bb restent \u00e0 \u00e9lucider. Ceci doit \u00eatre approfondi dans le cadre de recherches futures.<\/p>\n<\/li>\n<li>\n<p>Parmi les patients souffrant d&#39;une crise de migraine&#x002C; 19\u00a0\u00e0 31% des patients ne ressentent plus de douleur deux heures apr\u00e8s la prise de rim\u00e9g\u00e9pant&#x002C; soit 5 \u00e0 16% de plus qu&#39;avec le placebo. L&#39;effet semble \u00eatre du m\u00eame ordre de grandeur que celui d&#39;autres antimigraineux&#x002C; mais pour pouvoir en juger&#x002C; il faudrait des \u00e9tudes portant sur des populations comparables. Des \u00e9tudes comparatives directes sont n\u00e9cessaires pour mieux cerner la place du rim\u00e9g\u00e9pant au sein de l&#39;arsenal th\u00e9rapeutique.<\/p>\n<\/li>\n<li>\n<p>Le traitement par rim\u00e9g\u00e9pant pourrait s\u2019av\u00e9rer b\u00e9n\u00e9fique chez les patients migraineux qui ne r\u00e9pondent pas \u00e0 d\u2019autres traitements ou qui pr\u00e9sentent des contre-indications \u00e0 ces traitements&#x002C; mais ce groupe de patients n\u2019a pas fait l\u2019objet d\u2019\u00e9tudes randomis\u00e9es. Des recherches suppl\u00e9mentaires sont \u00e9galement n\u00e9cessaires en ce qui concerne les risques et les b\u00e9n\u00e9fices li\u00e9s \u00e0 l\u2019utilisation concomitante d\u2019anticorps monoclonaux.<\/p>\n<\/li>\n<li>\n<p>Le rim\u00e9g\u00e9pant utilis\u00e9 en prophylaxie permet de diminuer le nombre de jours de migraine de moins d&#39;un jour par mois. M\u00eame si pour le patient&#x002C; chaque jour sans migraine est un jour de gagn\u00e9&#x002C; il est important de ne pas cr\u00e9er de faux espoirs. Il n&#39;y a aucune garantie de succ\u00e8s th\u00e9rapeutique et il ne s\u2019agit pas d\u2019un traitement curatif.<\/p>\n<\/li>\n<li>\n<p>La r\u00e9ponse au placebo dans une population de patients souffrant de migraine s\u00e9v\u00e8re est importante (les patients avaient en moyenne 4 \u00e0 4&#x002C;6 crises de migraine par mois \u00e0 l\u2019inclusion dans les \u00e9tudes sur la migraine aigu\u00eb et en moyenne 10 jours de migraine par mois dans l&#39;\u00e9tude sur la prophylaxie).<\/p>\n<\/li>\n<li>\n<p>On peut se demander si le b\u00e9n\u00e9fice du rim\u00e9g\u00e9pant est proportionnel \u00e0 son prix \u00e9lev\u00e9&#x002C; qui&#x002C; \u00e0 environ 30 \u20ac par comprim\u00e9&#x002C; est beaucoup plus \u00e9lev\u00e9 que celui de la plupart des autres m\u00e9dicaments antimigraineux (sauf des anticorps monoclonaux). Le co\u00fbt social de la migraine s\u00e9v\u00e8re doit \u00eatre pris en compte dans cette \u00e9valuation.<\/p>\n<\/li>\n<li>\n<p>La migraine \u00e9tant une affection chronique&#x002C; il est fort probable que le traitement prophylactique sera pris pendant des ann\u00e9es. Les \u00e9tudes contr\u00f4l\u00e9es par placebo n\u2019ont \u00e9valu\u00e9 le rim\u00e9g\u00e9pant que sur une dur\u00e9e de tout au plus 3 mois&#x002C; ce qui laisse de nombreux points d&#39;interrogation quant \u00e0 son efficacit\u00e9 et sa s\u00e9curit\u00e9 d&#39;emploi \u00e0 long terme. En outre&#x002C; il n&#39;existe pas d&#39;\u00e9tudes de bonne qualit\u00e9 m\u00e9thodologique sur l\u2019effet apr\u00e8s l&#39;arr\u00eat du traitement.<\/p>\n<\/li>\n<li>\n<p>Les \u00e9tudes cliniques n&#39;ont pas r\u00e9v\u00e9l\u00e9 d&#39;effets ind\u00e9sirables graves&#x002C; mais elles portaient sur une population s\u00e9lectionn\u00e9e. Il faut attendre les r\u00e9sultats d\u2019\u00e9tudes post-commercialisation pour pouvoir se prononcer sur la s\u00e9curit\u00e9 du rim\u00e9g\u00e9pant&#x002C; en particulier chez les patients atteints de maladies cardiovasculaires graves ou de troubles psychiatriques.<\/p>\n<\/li>\n<li>\n<p>Il n&#39;est pas possible de se prononcer sur le profil d\u2019efficacit\u00e9 et d\u2019innocuit\u00e9 des antagonistes des r\u00e9cepteurs du CGRP chez les enfants et les adolescents en raison de l&#39;absence d&#39;\u00e9tudes randomis\u00e9es.<br \/> \u00a0<\/p>\n<\/li>\n<\/ul>\n<h2>Sources<\/h2>\n<p><span class=&quot;folia-referentie-tekst&quot;><span class=&quot;folia-referentie-nummer&quot;>1\u00a0<\/span>Heersche A&#x002C; Bijlstra-Cramer MA. Erenumab; de eerste CGRP-antagonist bij migraine. Pharma Selecta 2018;34:65-8.<\/span><br \/> <span class=&quot;folia-referentie-tekst&quot;><span class=&quot;folia-referentie-nummer&quot;>2\u00a0\u00a0<\/span>Schwarz EP. Nieuw geneesmiddel: rimegepant bij migraineaanvallen. Geneesmiddelenbulletin 2022;8:65-8.<br \/> <span class=&quot;folia-referentie-nummer&quot;>3\u00a0<\/span>EMA. EPAR-Assessment Report Vydura\u00ae. <a href=&quot;https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vydura&quot;>https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vydura<\/a><br \/> <span class=&quot;folia-referentie-nummer&quot;>4<\/span>\u00a0The Medical Letter on Drugs and Therapeutics. Rimegepant (Nurtec ODT) for acute treatment of migraine. The Medical Letter on Drugs and Therapeutics 2020;62:70-2. <a href=&quot;https:\/\/secure.medicalletter.org\/TML-article-1597d&quot;>https:\/\/secure.medicalletter.org\/TML-article-1597d<\/a><br \/> <span class=&quot;folia-referentie-nummer&quot;>5<\/span>\u00a0Mullin K&#x002C; Kudrow D&#x002C; Croop R&#x002C; et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology 2020;94:e2121-e5.doi:10.1212\/WNL.0000000000008944<\/span><br \/> <span class=&quot;folia-referentie-tekst&quot;><span class=&quot;folia-referentie-nummer&quot;>6<\/span>\u00a0Cohen F&#x002C; Yuan H&#x002C; Silberstein SD. Calcitonin Gene-Related Peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale. BioDrugs 2022;36:341-58.doi:10.1007\/s40259-022-00530-0<br \/> <span class=&quot;folia-referentie-nummer&quot;>7<\/span>\u00a0Marcus R&#x002C; Goadsby PJ&#x002C; Dodick D&#x002C; et al. BMS-927711 for the acute treatment of migraine: a double-blind&#x002C; randomized&#x002C; placebo controlled&#x002C; dose-ranging trial. Cephalalgia 2014;34:114-25.doi:10.1177\/0333102413500727<br \/> <span class=&quot;folia-referentie-nummer&quot;>8<\/span>\u00a0Yang C-P&#x002C; Liang C-S&#x002C; Chang C-M&#x002C; et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 2021;4:e2128544.doi:10.1001\/jamanetworkopen.2021.28544<br \/> <span class=&quot;folia-referentie-nummer&quot;>9<\/span>\u00a0Lipton RB&#x002C; Croop R&#x002C; Stock EG&#x002C; et al. Rimegepant&#x002C; an oral calcitonin gene-related peptide receptor antagonist&#x002C; for migraine. N Engl J Med 2019;381:142-9.doi:10.1056\/NEJMoa1811090<br \/> <span class=&quot;folia-referentie-nummer&quot;>10<\/span>\u00a0Croop R&#x002C; Goadsby PJ&#x002C; Conway CM&#x002C; et al. Efficacy&#x002C; safety&#x002C; and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised&#x002C; phase 3&#x002C; double-blind&#x002C; placebo-controlled trial. The Lancet 2019;31:737-45.doi:<a href=&quot;https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X&quot;>https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X<\/a><br \/> <span class=&quot;folia-referentie-nummer&quot;>11<\/span>VanderPluym JH&#x002C; Halker Singh RB&#x002C; Urtecho M&#x002C; et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA 2021;325:2357-69.doi:10.1001\/jama.2021.7939<br \/> <span class=&quot;folia-referentie-nummer&quot;>12<\/span>\u00a0Gao B&#x002C; Yang Y&#x002C; Wang Z&#x002C; et al. Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Front Pharmacol 2020;10:1577.doi:10.3389\/fphar.2019.01577<br \/> <span class=&quot;folia-referentie-nummer&quot;>13<\/span>\u00a0Derry CJ&#x002C; Derry S&#x002C; Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2:CD008615.doi:10.1002\/14651858.CD008615.pub2<br \/> <span class=&quot;folia-referentie-nummer&quot;>14<\/span>\u00a0McCarthy L. Orally disintegrating rimegepant increased freedom from pain and from most bothersome symptom at 2 h in acute migraine. Annals of Internal Medicine 2019;171:JC58-JC.doi:10.7326\/ACPJ201911190-058<br \/> <span class=&quot;folia-referentie-nummer&quot;>15<\/span>\u00a0Johnston K&#x002C; Harris L&#x002C; Powell L&#x002C; et al. Monthly migraine days&#x002C; tablet utilization&#x002C; and quality of life associated with Rimegepant &#8211; post hoc results from an open label safety study (BHV3000-201). J Headache Pain 2022;23:10.doi:10.1186\/s10194-021-01378-5<br \/> <span class=&quot;folia-referentie-nummer&quot;>16<\/span>\u00a0Croop R&#x002C; Lipton RB&#x002C; Kudrow D&#x002C; et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3&#x002C; randomised&#x002C; double-blind&#x002C; placebo-controlled trial. Lancet 2021;397:51-60.doi:10.1016\/S0140-6736(20)32544-7<br \/> <span class=&quot;folia-referentie-nummer&quot;>17<\/span>\u00a0Halker Singh R&#x002C; VanderPluym JH&#x002C; Morrow AS&#x002C; et al. Acute treatments for episodic migraine. Comparative Effectiveness Review. Number 239. AHRQ 2020;December. <a href=&quot;https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK566246\/&quot;>https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK566246\/<\/a><br \/> <span class=&quot;folia-referentie-nummer&quot;>18<\/span>\u00a0Anonymous. Vydura\u00ae &#8211; Samenvatting van de Kenmerken van het Product.<br \/> <span class=&quot;folia-referentie-nummer&quot;>19<\/span>\u00a0Pellesi L. Combining two CGRP inhibitors to treat migraine. Expert Opinion on Drug Safety 2022;21:1135-36.doi:10.1080\/14740338.2022.2130890<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le rim\u00e9g\u00e9pant appartient \u00e0 la classe des antagonistes des r\u00e9cepteurs  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,14914],"tags":[20213],"class_list":["post-181359","post","type-post","status-publish","format-standard","hentry","category-actualites","category-2023-fr","tag-import_tags"],"_links":{"self":[{"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/posts\/181359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/comments?post=181359"}],"version-history":[{"count":0,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/posts\/181359\/revisions"}],"wp:attachment":[{"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/media?parent=181359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/categories?post=181359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/tags?post=181359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}